Image not available
Chemicals
Abaloparatide CAS NO.247062-33-5
<p>Abaloparatide (CAS 247062-33-5) is a synthetic peptide analog of parathyroid hormone-related protein (PTHrP) engineered for the treatment of postmenopausal osteoporosis. This 34-amino acid therapeutic peptide specifically activates the parathyroid hormone 1 receptor (PTH1R), promoting bone formation and increasing bone mineral density. As a GMP-grade active pharmaceutical ingredient, it is supplied as a white to …
SupplierGlobal Technology Co., Ltd.www.hqtechtirz.com
Source categories
About this product
Product information from the supplier.
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | Abaloparatide |
| CAS NO. | 247062-33-5 |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C174H300N56O49 |
| Molecular Weight | 3960.59 g/mol |
| Purity (RP-HPLC) | ≥ 98.0% |
| Solubility | Soluble in water, phosphate buffer (pH 5.0-6.5), and 0.9% sodium chloride injection |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | Parathyroid hormone receptor 1 (PTH1R) agonist; stimulates bone formation, increases bone mineral density. |
| Storage Conditions | Store at 2-8°C, protected from light. After reconstitution, use immediately or store as directed (typically 2-8°C for 24 hours). |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
Abaloparatide functions as a selective agonist of the parathyroid hormone 1 receptor (PTH1R) on osteoblasts. By activating PTH1R signaling pathways, it stimulates new bone formation through increased osteoblast activity and differentiation. The peptide's modified structure provides preferential activation of the Gs/cAMP pathway over the Gq/PLC pathway, resulting in an anabolic bone-building effect with reduced bone resorption compared to other bone-active agents. This balanced action promotes significant increases in bone mass and structural integrity.
2.PRODUCT INDICATIONS
Postmenopausal Osteoporosis: Treatment of osteoporosis in postmenopausal women at high risk for fracture
Fracture Prevention: Reduction of vertebral and nonvertebral fracture risk in osteoporotic populations
Bone Health Management: Improvement of bone mineral density in patients with significant bone loss
Pharmaceutical Development: Active ingredient for osteoporosis treatment formulations
Research Applications: Studies of bone metabolism, osteoblast function, and anabolic bone therapies
3.CLINICAL EFFICACY OF PRODUCT
Bone Density Improvement: Demonstrated 9.2% increase in lumbar spine BMD and 2.7% increase in total hip BMD over 18 months
Fracture Risk Reduction: 86% reduction in vertebral fractures and 43% reduction in nonvertebral fractures in clinical trials
Rapid Onset: Significant BMD improvements observed as early as 3 months after treatment initiation
Safety Profile: Generally well-tolerated with hypercalcemia and dizziness as most common adverse events
Quality Standards: ≥98% HPLC purity with verified receptor binding activity and batch consistency
Regulatory Approval: FDA-approved therapeutic with established efficacy in postmenopausal osteoporosis
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
More from this supplier
Global Technology Co., Ltd.
